Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer

Sequist, L. V., Soria, J.-C., Goldman, J. W., Wakelee, H. A., Gadgeel, S. M., Varga, A., Papadimitrakopoulou, V., Solomon, B. J., Oxnard, G. R., Dziadziuszko, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413654 · Cited by 665 · see citing works

Metformin Sensitizes EGFR-TKI–Resistant Human Lung Cancer Cells In Vitro and In Vivo through Inhibition of IL-6 Signaling and EMT Reversal

Li, L., Han, R., Xiao, H., Lin, C., Wang, Y., Liu, H., Li, K., Chen, H., Sun, F., Yang, Z., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2613 · Cited by 236 · see citing works

Survival of Patients with Stage IV Lung Cancer with Diabetes Treated with Metformin

Lin, J. J., Gallagher, E. J., Sigel, K. M., Mhango, G., Galsky, M. D., Smith, C. B., LeRoith, D., & Wisnivesky, J. P. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201407-1395oc · Cited by 137 · see citing works

Metformin suppresses pregnane X receptor (PXR)-regulated transactivation of CYP3A4 gene

Krausová, L., Stejskalová, L., Wang, H., Vrzal, R., Dvořák, Z., Mani, S., & Pávek, P. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.08.023 · Cited by 96 · see citing works

Lung cancer: current therapies and new targeted treatments

Hirsch, F. R., Scagliotti, G. V., Mulshine, J. L., Kwon, R., Curran, W. J., Wu, Y.-L. L. C., & Paz-Ares, L. G. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30958-8 · Cited by 3,278 · see citing works

New and emerging targeted treatments in advanced non-small-cell lung cancer

Hirsch, F. R., Suda, K., Wiens, J., & Bunn, P. A. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31473-8 · Cited by 493 · see citing works

EGFR-TKIs resistance via EGFR-independent signaling pathways

Liu, Q., Yu, S., Zhao, W., Qin, S., Chu, Q., & Wu, K. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0793-1 · Cited by 413 · see citing works

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works

Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Thompson, J. C., Yee, S. S., Troxel, A. B., Savitch, S. L., Fan, R., Balli, D., Lieberman, D. B., Morrissette, J. D., Evans, T. L., Bauml, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1231 · Cited by 325 · see citing works

Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review)

He, J., Huang, Z., Han, L., Gong, Y. Q., & Xie, C. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5270 · Cited by 321 · see citing works

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma

Krug, A. K., Enderle, D., Karlovich, C., Priewasser, T., Bentink, S., Spiel, A., Brinkmann, K., Emenegger, J., Grimm, D. G., Castellanos-Rizaldos, E., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx765 · Cited by 272 · see citing works

EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer

Wang, S., Tsui, S. T., Liu, C., Song, Y., & Liu, D. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0290-1 · Cited by 204 · see citing works

Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC

Kim, Y., Lee, B., Shim, J. H., Lee, S.-H., Park, W.-Y., Choi, Y.-L., Sun, J.-M., Ahn, J. S., Ahn, M.-J., & Park, K. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.10.150 · Cited by 174 · see citing works

Targeting EGFR in Lung Cancer: Current Standards and Developments

Díaz-Serrano, A., Gella, P., Jiménez, E., Zugazagoitia, J., & Paz-Ares Rodríguez, L. (2018) · Drugs · doi:10.1007/s40265-018-0916-4 · Cited by 108 · see citing works

The next tier of EGFR resistance mutations in lung cancer

Tumbrink, H. L., Heimsoeth, A., & Sos, M. L. (2020) · Oncogene · doi:10.1038/s41388-020-01510-w · Cited by 101 · see citing works

Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors

Wang, S., Song, Y., Yan, F., & Liu, D. (2016) · Frontiers of Medicine · doi:10.1007/s11684-016-0488-1 · Cited by 96 · see citing works

Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR- Mutant Lung Cancer

Tanimoto, A., Takeuchi, S., Arai, S., Fukuda, K., Yamada, T., Roca, X., Ong, S. T., & Yano, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2271 · Cited by 88 · see citing works

Natural tyrosine kinase inhibitors acting on the epidermal growth factor receptor: Their relevance for cancer therapy

Liang, Y., Zhang, T., & Zhang, J. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105164 · Cited by 77 · see citing works

Enhanced Glycolysis Supports Cell Survival in EGFR-Mutant Lung Adenocarcinoma by Inhibiting Autophagy-Mediated EGFR Degradation

Kim, J. H., Nam, B., Choi, Y. J., Kim, S. Y., Lee, J., Sung, K. J., Kim, W. S., Choi, C., Chang, E., Koh, J. S., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0117 · Cited by 75 · see citing works

Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR -Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target

Song, K.-A., Hosono, Y., Turner, C., Jacob, S., Lochmann, T. L., Murakami, Y., Patel, N. U., Ham, J., Hu, B., Powell, K. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0304 · Cited by 66 · see citing works

Addressing the challenges of applying precision oncology

Shin, S. H., Bode, A. M., & Dong, Z. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0032-z · Cited by 61 · see citing works

Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition

Lou, W., Chen, Y., Zhu, K., Deng, H., Wu, T., & Wang, J. (2017) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b17-00271 · Cited by 61 · see citing works

An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors

Mancini, M., Gal, H., Gaborit, N., Mazzeo, L., Romaniello, D., Salame, T. M., Lindzen, M., Mahlknecht, G., Enuka, Y., Burton, D. G. A., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201708076 · Cited by 51 · see citing works

Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells

Sesumi, Y., Suda, K., Mizuuchi, H., Kobayashi, Y., Sato, K., Chiba, M., Shimoji, M., Tomizawa, K., Takemoto, T., & Mitsudomi, T. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.12.012 · Cited by 44 · see citing works

Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer

Li, X., & Zhou, C. (2017) · Oncotarget · doi:10.18632/oncotarget.19007 · Cited by 43 · see citing works

Overcoming Resistance to Targeted Therapies in Cancer

Redmond, K. L., Papafili, A., Lawler, M., & Schaeybroeck, S. V. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.028 · Cited by 39 · see citing works

TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells

Wu, D.-W., Chen, T.-C., Huang, H., & Lee, H. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.192 · Cited by 39 · see citing works

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A

Chiba, M., Togashi, Y., Bannno, E., Kobayashi, Y., Nakamura, Y., Hayashi, H., Terashima, M., Velasco, M. A. D., Sakai, K., Fujita, Y., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3263-z · Cited by 38 · see citing works

Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance.

Villadolid, J. J., Ersek, J. L., Fong, M. K., Sirianno, L., & Story, E. S. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.10.01 · Cited by 37 · see citing works

The End of Nihilism: Systemic Therapy of Advanced Non–Small Cell Lung Cancer

Ernani, V., Steuer, C. E., & Jahanzeb, M. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-042915-102442 · Cited by 29 · see citing works

Resistance of Lung Cancer to EGFR-Specific Kinase Inhibitors: Activation of Bypass Pathways and Endogenous Mutators

Marrocco, I., & Yarden, Y. (2023) · Cancers · doi:10.3390/cancers15205009 · Cited by 28 · see citing works

Dacomitinib in lung cancer: a &amp;ldquo;lost generation&amp;rdquo; EGFR tyrosine-kinase inhibitor from a bygone era?

Ou, S.-H., & Soo, R. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s52787 · Cited by 28 · see citing works

A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations

Yu, H. A., Spira, A. I., Horn, L., Weiss, J. M., West, H., Giaccone, G., Evans, T. L., Kelly, R. J., Desai, B., Krivoshik, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1447 · Cited by 27 · see citing works

Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives

Genova, C., Rossi, G., Tagliamento, M., Rijavec, E., Biello, F., Cerbone, L., Zullo, L., & Grossi, F. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1714441 · Cited by 26 · see citing works

Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer

Choo, J. R.-E., Tan, C., & Soo, R. A. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0554-5 · Cited by 24 · see citing works

Updates in the molecular pathology of non-small cell lung cancer

Paver, E. C., O'Toole, S. A., Cheng, X. M., Mahar, A. M., & Cooper, W. A. (2021) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2021.04.001 · Cited by 21 · see citing works

Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?

Pi, C., Zhang, M., Peng, X., Zhang, Y., Xu, C., & Zhou, Q. H. (2017) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2017.1395701 · Cited by 21 · see citing works

Non-invasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer

Berz, D., Raymond, V. M., Garst, J. H., & Erlander, M. G. (2015) · Experimental Hematology and Oncology · doi:10.1186/s40164-016-0052-3 · Cited by 20 · see citing works

AZD9291 Increases Sensitivity to Radiation in PC-9-IR Cells by Delaying DNA Damage Repair after Irradiation and Inducing Apoptosis

Wu, S., Zhu, L., Tu, L., Sumei Chen, Huang, H., Zhang, J., Ma, S., & Zhang, S. (2018) · Radiation Research · doi:10.1667/rr14682.1 · Cited by 20 · see citing works

Current status of clinical proteogenomics in lung cancer

Nishimura, T., Nakamura, H., Végvári, Á., Marko‐Varga, G., Furuya, N., & Saji, H. (2019) · Expert Review of Proteomics · doi:10.1080/14789450.2019.1654861 · Cited by 19 · see citing works

Marked Differences in CNS Activity among EGFR Inhibitors: Case Report and Mini-Review

Pareek, V., Welch, M. R., Ravera, E., Zampolin, R. L., Sequist, L. V. D., & Halmos, B. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.07.010 · Cited by 18 · see citing works

Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine

Lazaro, T. T., & Brastianos, P. K. (2017) · CNS Oncology · doi:10.2217/cns-2016-0038 · Cited by 18 · see citing works

Pd-L1 Expression and Egfr Status In Advanced Non-Small-Cell Lung Cancer Patients Receiving Pd-1/Pd-L1 Inhibitors: A Meta-Analysis

Li, J., & Gu, J. H. (2019) · Future Oncology · doi:10.2217/fon-2018-0639 · Cited by 18 · see citing works

Multi or Single-Kinase Inhibitors to Counteract Drug Resistance in Cancer: What is New?

Pecoraro, C., Carbone, D., Cascioferro, S., Parrino, B., & Diana, P. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220729152741 · Cited by 17 · see citing works

Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer

Bhateja, P., Dowlati, A., & Sharma, N. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0515-3 · Cited by 17 · see citing works

Detection of EGFR Mutations in Plasma Cell-Free Tumor DNA of TKI-Treated Advanced-NSCLC Patients by Three Methodologies: Scorpion-ARMS, PNAClamp, and Digital PCR

Siggillino, A., Ulivi, P., Pasini, L., Reda, M. S., Chiadini, E., Tofanetti, F. R., Baglivo, S., Metro, G., Crinò, L., Delmonte, A., et al. (2020) · Diagnostics · doi:10.3390/diagnostics10121062 · Cited by 17 · see citing works

Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer

Kasahara, N., Kenmotsu, H., Serizawa, M., Umehara, R., Ono, A., Hisamatsu, Y., Wakuda, K., Omori, S., Nakashima, K., Taira, T., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.02.001 · Cited by 16 · see citing works

Advances in drug development for targeted therapies for glioblastoma

Ge, Y., Wang, Y., Chen, J., Zheng, W., Liu, C., Chen, S., Wang, L., Luo, J., & Li, Z. (2020) · Medicinal Research Reviews · doi:10.1002/med.21676 · Cited by 14 · see citing works

Telmisartan Facilitates the Anticancer Effects of CARP-1 Functional Mimetic and Sorafenib in Rociletinib Resistant Non-small Cell Lung Cancer

Surapaneni, S. K., Nottingham, E., Mondal, A., Patel, N., Arthur, P., Gebeyehu, A., Kalvala, A. K., Rishi, A. K., & Singh, M. S. (2021) · Anticancer Research · doi:10.21873/anticanres.15226 · Cited by 15 · see citing works

Hyperglycaemia Induced by Novel Anticancer Agents: An Undesirable Complication or a Potential Therapeutic Opportunity?

Shah, R. R. (2016) · Drug Safety · doi:10.1007/s40264-016-0485-y · Cited by 13 · see citing works

Developments for Personalized Medicine of Lung Cancer Subtypes: Mass Spectrometry-Based Clinical Proteogenomic Analysis of Oncogenic Mutations

Nishimura, T., & Nakamura, H. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-42316-6_8 · Cited by 9 · see citing works

Identification of the structural features of quinazoline derivatives as EGFR inhibitors using 3D-QSAR modeling, molecular docking, molecular dynamics simulations and free energy calculations

Wang, F., Yang, W., Liu, H., & Zhou, B. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1956591 · Cited by 9 · see citing works

Chromosomal Copy Number Variation Predicts EGFR-TKI Response and Prognosis for Patients with Non-Small Cell Lung Cancer

He, H., Ma, H., Chen, Z., Chen, J., Wu, D., Lv, X., & Zhu, J. (2023) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s418320 · Cited by 9 · see citing works

Serum microRNA-365 suppresses non-small-cell lung cancer metastasis and invasion in patients with bone metastasis of lung cancer

Liu, Y., Jia, J., Song, B., Qiu, H., Liang, G., Zhang, B., & Wang, K. (2020) · Journal of International Medical Research · doi:10.1177/0300060520939718 · Cited by 7 · see citing works

Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer

Wang, H.-Y., Chang, Y., Cheng, C.-C., Chao, M., Lin, S.-I., Pan, S., Hsu, C.-C., Liu, T., Cheng, H.-C., Tseng, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13185 · Cited by 7 · see citing works

Comparative efficacy and safety of first‑line PD‑1/PD‑L1 inhibitors in immunotherapy for non‑small cell lung cancer: A network meta‑analysis

Liu, L., Yan, Y., Wang, Y., Li, Z., Yang, L., Yu, K., & Zhao, Z. (2025) · Oncology Letters · doi:10.3892/ol.2025.14903 · Cited by 6 · see citing works

Beware the TIGER‐X's stripes: rapid cataract formation in patients taking Rociletinib

Rao, A. C., Tiuseco, K., Yun, S., & White, A. J. R. (2016) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.12906 · Cited by 5 · see citing works

Efficacy and safety of nivolumab for advanced/recurrent non-small-cell lung cancer: an up-to-date meta-analysis of large-scale phase III randomized controlled trials

Zhang, H., Zhang, L., Chen, K., & Chen, G. (2022) · Future Oncology · doi:10.2217/fon-2022-0081 · Cited by 5 · see citing works

Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer

Kim, D. H., Choi, Y. J., Kim, S. Y., Lee, J., Sung, K. J., Sung, Y. H., Kim, S.-E., Kim, S.-E., Ryu, H. C., Kim, J. S., et al. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0568-z · Cited by 4 · see citing works

Epidermal growth factor receptor (EGFR) atypical mutations in non-small-cell lung cancer (NSCLC): ‘Where the streets have no name’

Spitaleri, G., Aliaga, P. T., Mariani, G. A., Attili, I., Signore, E. D., Corvaja, C., Napoli, V. M., Cavallone, M., Etessami, J. D., Zhan, Y., et al. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105327 · Cited by 2 · see citing works

Development and Validation of an LC-MS/MS Method for Quantitative Determination of EAI045, A Novel EGFR Inhibitor, in Rat Plasma

Chu, Z., Xue, M., & Xiong, S. (2019) · Current Pharmaceutical Analysis · doi:10.2174/1573412915666190206125557 · Cited by 2 · see citing works

The use of biomarkers in the treatment of non-small cell lung cancer

Baumgart, M. A., & Pandya, K. J. (2016) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2016.1136558 · Cited by 2 · see citing works

Validation of Cell-Free DNA Collection Tubes for Determination of EGFR Mutation Status in Liquid Biopsy from NSCLC Patients

Sesé, M., Somoza, R., Maestu, I., Ureste, M. M., Sánchez, A., Cordoba, J. F., Sansano, I., Venturas, G., y Cajal, S. R., & Hernández‐Losa, J. (2019) · Oncology and Therapy · doi:10.1007/s40487-019-00099-9 · Cited by 2 · see citing works

Efficacy and safety of pembrolizumab for treating advanced non-small-cell lung cancer: a meta-analysis of phase II and III randomized controlled trials

Gong, T., Liu, L., Liu, Y., Liu, K., Yang, Y., Li, L., & Zhang, C. (2021) · Journal of Chemotherapy · doi:10.1080/1120009x.2021.2014714 · Cited by 1 · see citing works

Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is the Issue

Dayanc, B., Eris, S., & Şentürk, Ş. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_54

Une nouvelle stratégie thérapeutique pour prolonger la réponse du cancer bronchique aux inhibiteurs d’EGFR en prévenant l’émergence des cellules résistantes

Brunet, L. (2021) · theses.fr (ABES) · doi:10.70675/a4e459eez153dz4ec7z924fza1c1c6e4fdd6

3088 Efficacy of rociletinib (co-1686) in EGFR-mutant non-small cell lung cancer (NSCLC) patients (pts) assessed with a plasma EGFR test

Gadgeel, S. M., Soria, J., Goldman, J. W., Wakelee, H. A., Camidge, D. R., Yu, H., Varga, A., Solomon, B., Oxnard, G. R., Ou, S. H., et al. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(16)31729-4 · Cited by 1 · see citing works

3009 Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvement

Varga, A., Camidge, D. R., Sequist, L. V. D., Wakelee, H. A., Ou, S. ‐. I., Goldman, J. W., Papadimitrakopoulou, V., Gadgeel, S. M., Mekhail, T. M., Oxnard, G. R., et al. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(16)31654-9 · Cited by 13 · see citing works

Rociletinib for EGFR-mutated Non–Small-Cell Lung Cancer

Tsao, A. S. (2015) · Journal watch · doi:10.1056/nejm-jw.na37701 · Cited by 54 · see citing works

P2.03-058 Tiger-3: A Phase 3 Randomized Study of Rociletinib Vs Chemotherapy in EGFR-mutated Non-small Cell Lung Cancer (NSCLC)

Yang, J. C., Reckamp, K. L., Kim, Y., Novello, S., Smit, E. F., Lee, J. H., Su, W., Akerley, W., Blakely, C. M., Bazhenova, L. A., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.11.013 · Cited by 3 · see citing works

Erlotinib or Gefitinib for Non–Small-Cell Lung Cancer

Kaye, F. J., Jantz, M. A., & Dallas, J. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1103918 · Cited by 10 · see citing works